This may be via the suppression of CIP2A, as treating NSCLC cell lines without EGFR mutations with these TKIs and derivatives like TD-19 was associated with the down regulation of CIP2A [94, 104, 106]. Here, CIP2A is linked to non-small cell lung carcinoma.